Posts Tagged ‘Cancer’

peter sadler

June 23rd, 2010

The hundred or so elements of the Periodic Table determine everything we do, what our universe is made of, how the body’s biochemistry works, the drugs we take, the clothes we wear, the TV screens we watch . . . they make up the fabric, the substance of life.

Professor Peter Sadler, whose research field is inorganic chemistry, the stuff of the Periodic Table, works at the interdisciplinary borders of inorganic chemistry, biology and medicine.

Which of the 81 stable elements on earth, he asks, are essential for life? Can the genome tell us? Probably not . . . We think certain metals, for example vanadium, chromium, nickel and tin are essential, but actually we know very little about them. If they are essential, should we be using them in medicine?

The basis of many therapies are carbon (organic) compounds. Many inorganic elements, however, are more difficult to study than carbon. Professor Sadler argues that the challenges and the scope for radical discovery lie here.

Professor Peter Sadler is Head of Warwick’s Chemistry Department. His research interests are the chemistry of metals in medicine (bioinorganic chemistry, inorganic chemical biology and medicine), and the design and chemical mechanism of action of therapeutic metal complexes, including organometallic arene anticancer complexes, photoactivated metal anticancer complexes (for photochemotherapy), metallomacrocycles as antivirals and stem-cell-mobilising agents, and metalloantibiotics. Besides synthesis of co-ordination complexes, his research involves studies of interactions with targets such as RNA, DNA and proteins, and often industrial and international interdisciplinary collaborations.

yvonne perrie

June 19th, 2010

The necessity for new vaccines is urgent and evident. Despite humanity’s success in eradicating smallpox, two other infectious diseases — malaria and TB, remains tow of the world’s primary killers. The combination of either with HIV is lethal. Infectious agents are also implicated as causes of cancer.

There is good news, though says Professor Yvonne Perrie of Aston University. Several laboratories around the world are working on new vaccines and their delivery. Indeed her own research is focused on the advancements and strategic development of drug delivery systems to facilitate effective delivery and targeting of drugs and of vaccines.

Yvonne Perrie is Professor in Pharmaceutics and Drug Delivery, as well as being Head of Pharmacy at Aston University. She is also co-author (with Thomas Rades) of FASTtrack: Pharmaceutics – Drug Delivery and Targeting.

The specific fields of her research are the formulation engineering of vaccines (including conventional and DNA vaccines); enhancing solubility and delivery of bioactive molecules using colloid science and technology; the delivery of drugs, vaccines and gene therapies using liposomes, niosomes and other novel particulate systems; the design, physicochemical characterisation and development of non-viral systems for gene delivery; tissue engineering and regenerative medicine as well as enhancing learning methods in Pharmacy Education.

charles craddock

June 10th, 2010

Some kinds of leukemia and myeloma have been traditionally very difficult to treat, and put patients through punishing chemotherapy which only sometimes worked. This situation has recently changed dramatically.

Charles Craddock Director of the Blood and Marrow Transplant Unit at University Hospital Birmingham NHS Foundation Trust says there are now exciting novel transplant and drug therapies, transforming patients’ lives, enabling many to live longer and fuller lives than was ever thought possible only a few years ago.

Charles Craddock is Professor of Haematolo-oncology at the University of Birmingham as well as Director of the Blood and Marrow Transplant Unit at University Hospital Birmingham NHS Foundation Trust. He has a particular research interest in the development of novel transplant and drug therapies in leukemia and myeloma. He also works with groups researching chromatin structure in acute-myeloid leukemia, mechanisms of drug resistance in myeloma and characterisaation of dysregulated signalling pathways in leukemia using proteomics.

philip johnson

June 10th, 2010

“The UK is the best place in the world to run trials, with consequent ‘wealth and health’ benefits,” so says Philip Johnson, Director of the Cancer Research UK Clinical Trails Unit as well as Professor of Oncology and Translational Research at the University of Birmingham. In The New Optimists he argues why clinical trials are so important, and the kind of impact they have on treatments and patient care across the world.

Professor Johnson developed his interest in clinical trials and hepatobiliary cancer whilst at the Institute of Liver Studies, Kings College Hospital, London where he subsequently became Assistant Director. In 1992, he was appointed to the Chair of Clinical Oncology at the Chinese University of Hong Kong where he also became Director of the Cancer Centre and developed the Comprehensive Clinical Trials Unit whilst furthering his research interests into molecular biomarkers of cancer and new approaches to the treatment of live cancer.

andrew peet

June 10th, 2010

The clinical treatment of brain tumours in children is undergoing a revolution because of new scanning techniques; i.e. ever more illuminating non-invasive brain imaging of several kinds. The medics caring for these children now have a far better understanding of what the tumour is and where it is — and so can provide far more effective treatments.

Dr Andrew Peet is at the forefront of research in this area, and is a clinician too, being both a Clinical Research Fellow and Honorary Consultant Paediatric Oncologist at the University of Birmingham and the Oncology Department at Birmingham Children’s Hospital.

His research is on new scanning techniques and, in his contribution to The New Optimists, he explains how CT scans provided the first breakthrough, and now how magnetic resonance spectroscopy and other complementary functional imaging techniques are revolutionising both our understanding and the treatment of brain tumours.

nicholas james

June 10th, 2010

Nick James is at the forefront of the battle against cancer. In his paper about targeted therapies (in Part 1: Microcosm: Tackling the big challenges in The New Optimists) he explains the latest cancer treatments, particularly the success, but also the cost of targeted molecular approaches to cancer treatment.

As Professor of Clinical Oncology at the University of Birmingham and the Queen Elizabeth Hospital Birmingham, Nick James’ current research focusses on urological tumours, and he leads a number of international trials. In 1994, he co-founded the leading patient website, CancerHelpUK which has won numerous awards.

He qualified from St Bartholomew’s Hospital with the principal class prize in medicine. After general training in London and Brussels, he undertook oncology training at Hammersmith, the Royal Marsden, St Marys and St Bartholomew’s Hospitals and at the Cancer Institute, Tokyo.

derek alderson

June 10th, 2010

Professor Derek Alderson holds the Baring Chair of Surgery at the University of Birmingham. Current Editor of the British Journal of Surgery, his main area of clinical interest is in oesophago-gastric surgery.

His contribution to The New Optimists is Part 1: The Microcosm: Tackling the big challenges, Editor Keith Richards mentions it in his Introduction as it is an illustration of how the practical doing of science raises not just answers, but much more interestingly,  raises questions waiting to be answered:

” . . . over the last forty years the incidence of oesophageal adenocarcinoma has risen from just one tenth to three-quarters of all oesophageal cancers in the UK and that the UK has the highest incidence of this form of cancer in the world, but as yet we don’t know why. The writers in this collection convey the excitement, and sometimes the urgency of confronting questions such as these. Theirs is an optimism grounded in engagements of this kind — and it is all the more inspiring for that.”

paul moss

June 5th, 2010

That cancer can be controlled within a generation is an optimistic viewpoint. Coming from Professor Paul Moss, a clinical haematologist as well as Head of the School of Cancer Studies at the University of Birmingham, it is a cogent argument arising from a deep understanding of the complexities of the one of the biggest challenges in medical research, and not some wildly hopeful assertion.

It is the argument he puts forward in the first essay in The New Optimists.

Professor Moss’ particular research interest is in the role of the immune system in the protection from cancer and viral infection. He is also one of the panelists for the British Science Festival event on 15th September 2010, chaired by Sue Beardsmore — so you have the opportunity to talk with him face-to-face. Please do come, or participate on-line — more information about how to do so will be posted shortly.